Holen Sie sich die Stockscreener-App
4.39
1.39%
0.06
Handel nachbörslich:
4.40
0.01
+0.23%
Schlusskurs vom Vortag:
$4.33
Offen:
$4.37
24-Stunden-Volumen:
154.67K
Relative Volume:
0.43
Marktkapitalisierung:
$285.50M
Einnahmen:
$207.32M
Nettoeinkommen (Verlust:
$-61.04M
KGV:
-4.5839
EPS:
-0.9577
Netto-Cashflow:
$-25.97M
1W Leistung:
-2.44%
1M Leistung:
-6.60%
6M Leistung:
+202.76%
1J Leistung:
-29.87%
1-Tages-Spanne:
$4.22
$4.41
1-Wochen-Bereich:
$4.22
$4.63
52-Wochen-Spanne:
$1.17
$7.08
Treace Medical Concepts Inc Stock (TMCI) Company Profile
Firmenname
Treace Medical Concepts Inc
Sektor
Branche
Telefon
(904) 373-5940
Adresse
100 PALMETTO PARK PLACE, PONTE VEDRA
Compare TMCI vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TMCI
Treace Medical Concepts Inc
|
4.39 | 292.66M | 207.32M | -61.04M | -25.97M | -0.9577 |
ABT
Abbott Laboratories
|
97.50 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.38 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.43 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.60 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.15 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Treace Medical Concepts Inc Stock (TMCI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-07 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-11-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-02-04 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-12-31 | Eingeleitet | Lake Street | Buy |
| 2024-12-17 | Fortgesetzt | JP Morgan | Neutral |
| 2024-05-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-05-08 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-05-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-05-08 | Herabstufung | Stifel | Buy → Hold |
| 2024-05-08 | Herabstufung | Truist | Buy → Hold |
| 2023-09-29 | Eingeleitet | UBS | Buy |
| 2023-05-01 | Eingeleitet | Truist | Buy |
| 2023-04-11 | Eingeleitet | Stephens | Equal-Weight |
| 2022-05-12 | Eingeleitet | BTIG Research | Buy |
| 2022-01-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-05-18 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-05-18 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-18 | Eingeleitet | Stifel | Buy |
Alle ansehen
Treace Medical Concepts Inc Aktie (TMCI) Neueste Nachrichten
Treace Medical Concepts Inc (TMCI-Q) Stock Price and News - The Globe and Mail
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Stock Has Consensus Target Price of $5.17 According to Brokerages - MarketBeat
Bank of America Corp DE Acquires 3,305,100 Shares of Treace Medical Concepts, Inc. $TMCI - MarketBeat
Investigation launched into Treace Medical offi... - Pluang
Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - reformer.com
Treace Medical Concepts, Inc. (TMCI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Treace Medical Concepts, Inc. (TMCI) stock price, news, quote and history - uk.finance.yahoo.com
Treace Medical (TMCI) Reports Five-Year Bunion Results. Can Evidence Drive Adoption? - Insider Monkey
Treace Medical Looks Unlikely To Recover, A Founder-Led Broken Growth Story (NASDAQ:TMCI) - Seeking Alpha
Treace Medical Concepts, Inc. (TMCI) Stock Analysis: Unveiling A 21.41% Upside Potential - DirectorsTalk Interviews
Treace Medical Concepts Presents 5-Year ALIGN3D, 2-Year MTA3D and SPRINT Clinical Study Results at AOFAS Annual Meeting - Quiver Quantitative
Treace Medical Concepts Announces Results of Three Clinical Studies Including the Milestone Five-Year Align3d Study Demonstrating Sustained Positive Outcomes of the Lapiplasty Procedure - marketscreener.com
96.6% of patients showed healing after foot surgery - Stock Titan
Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting - Orthopedics This Week
Treace Medical Concepts to Showcase New Foot and Ankle Innovations and Clinical Data at AOFAS 2026 - Quiver Quantitative
New bunion tools and five-year study results will be shown in Seattle - Stock Titan
Treace Medical Concepts, Inc. Stock Price Prediction: Today, Tomorrow, Next Week (TMCI) - Traders Union
BlackRock Inc. Takes Position in Treace Medical Concepts, Inc. $TMCI - marketbeat.com
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Given Consensus Recommendation of "Reduce" by Analysts - marketbeat.com
TMCI IMPORTANT DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Treace Medical Concepts, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class ActionTMCI - TMX Newsfile
Treace Medical (TMCI) Holds Gains: Stock Rises 1.09% as $4.42 Support Anchors the ChartMerger Arbitrage - vinanet.vn
Bank of America Corp DE Has $4.31 Million Stock Holdings in Treace Medical Concepts, Inc. $TMCI - marketbeat.com
Treace Medical Concepts (TMCI) Gains 0.87% as Shares Approach Key Resistance at $4.87Trend Reversal Picks - siam.in
TMCI Q2 2026 Earnings: Loss Narrows More Than Expected, Driving Modest Share GainsEarnings Surprise Stocks - dars.gov.et
SNDL And 2 Other Promising Penny Stocks To Watch - simplywall.st
Treace Medical (TMCI) CEO adds to stake with late‑August buys - Stock Titan
Treace Medical Concepts, Inc. (TMCI) Investigation: Bronstein, Ge - natlawreview.com
TMCI senior director charged with insider trading in U.S. - Peoples Gazette Nigeria
Exec charged for trading ahead of dismal results - Investment Executive
Did You Lose Money on Treace Medical Concepts, Inc. (TMCI)? Levi - The National Law Review
Treace Medical Concepts Earnings Call Signals Cautious Rebound - TipRanks
Medical Device Exec Cashed In On Bad Quarter, Feds Charge - Law360
522,900 Shares in Treace Medical Concepts, Inc. $TMCI Purchased by Renaissance Technologies LLC - MarketBeat
TMCI Q2 2026 Earnings: EPS Beat Drives 6.2% Stock Uptick as Losses NarrowProfit Warning Alert - vinanet.vn
Armistice Capital (TMCI) discloses 6.36M-share Treace Medical ownership stake - Stock Titan
Treace Medical Concepts (TMCI) officer disposes shares for tax or exercise costs - Stock Titan
Treace Medical Concepts (TMCI) CEO John T. Treace reports 19.2% beneficial stake - Stock Titan
Treace Medical Concepts (TMCI) CFO uses 37,102 shares to cover equity-related taxes - Stock Titan
Treace Medical Concepts (TMCI) officer uses 16,253 shares for tax or exercise costs - Stock Titan
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50 - simplywall.st
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Given Consensus Rating of "Reduce" by Analysts - marketbeat.com
Treace Medical Concepts (NASDAQ:TMCI) Price Target Raised to $5.00 at Truist Financial - MarketBeat
Finanzdaten der Treace Medical Concepts Inc-Aktie (TMCI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Treace Medical Concepts Inc-Aktie (TMCI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Treace John T. | Chief Executive Officer |
Aug 24 '26 |
Buy |
4.34 |
11,000 |
47,731 |
7,404,383 |
| Treace John T. | Chief Executive Officer |
Aug 21 '26 |
Buy |
4.35 |
5,000 |
21,748 |
7,393,383 |
| Treace John T. | Chief Executive Officer |
Jun 10 '26 |
Buy |
4.02 |
29,430 |
118,426 |
7,353,263 |
| Treace John T. | Chief Executive Officer |
Jun 11 '26 |
Buy |
4.04 |
22,887 |
92,541 |
7,376,150 |
| Treace John T. | Chief Executive Officer |
Jun 01 '26 |
Buy |
3.56 |
50,000 |
177,915 |
7,323,833 |
| Treace John T. | Chief Executive Officer |
May 28 '26 |
Buy |
3.02 |
61,202 |
184,824 |
7,273,833 |
| Treace John T. | Chief Executive Officer |
May 27 '26 |
Buy |
2.87 |
49,810 |
143,189 |
7,212,631 |
| Treace John T. | Chief Executive Officer |
May 26 '26 |
Buy |
2.79 |
4,508 |
12,576 |
7,162,821 |
| Treace John T. | Chief Executive Officer |
May 14 '26 |
Buy |
2.62 |
61,750 |
161,495 |
7,158,313 |
| Treace John T. | Chief Executive Officer |
May 13 '26 |
Buy |
2.46 |
49,013 |
120,533 |
7,096,563 |
0.26%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):